BRIGHT-Mind: Brain Response to an Intervention Using Guided, At-Home Technology for the Mind

Sponsor
Lumos Labs, Inc. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05912556
Collaborator
(none)
834
1
2
17.5
47.5

Study Details

Study Description

Brief Summary

The objective of this study is to assess the effectiveness of two digital programs for providing mental stimulation, improving cognition, and inducing changes in brain structure and function.

Condition or Disease Intervention/Treatment Phase
  • Device: Digital Program 1
  • Device: Digital Program 2
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
834 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Brain Response to an Intervention Using Guided, At-Home Technology for the Mind - A Randomized, Controlled, Double-blinded, Parallel-group Intervention Study to Assess an At-Home Program for Improving Cognition and Inducing Changes in Brain Structure and Function
Anticipated Study Start Date :
Jun 16, 2023
Anticipated Primary Completion Date :
Jul 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Other: Cohort A

Remote-Only subjects

Device: Digital Program 1
2/3 of randomized subjects use digital program 1 for 12 weeks to provide mental stimulation

Device: Digital Program 2
1/3 of randomized subjects use digital program 2 for 12 weeks to provide mental stimulation

Other: Cohort B

Remote + Imaging subjects

Device: Digital Program 1
2/3 of randomized subjects use digital program 1 for 12 weeks to provide mental stimulation

Device: Digital Program 2
1/3 of randomized subjects use digital program 2 for 12 weeks to provide mental stimulation

Outcome Measures

Primary Outcome Measures

  1. Overall Composite from Creyos (formerly Cambridge Brain Sciences) [Study Day 0 to Study Day 84]

    The Overall Composite is derived from the 12 tests in the Creyos battery.

Secondary Outcome Measures

  1. Concentration Domain Score from Creyos [Study Day 0 to Study Day 84]

  2. Memory Domain Score from Creyos [Study Day 0 to Study Day 84]

  3. Planning Domain Score from Creyos [Study Day 0 to Study Day 84]

  4. Reasoning Domain Score from Creyos [Study Day 0 to Study Day 84]

  5. Structural Brain Composite from Magnetic Resonance Imaging (MRI) [Study Day 0 to Study Day 84]

  6. White Matter Microstructure Composite from Diffusion Magnetic Resonance Imaging (dMRI) [Study Day 0 to Study Day 84]

  7. Within-Network Functional Connectivity from Resting-State functional Magnetic Resonance Imaging (fMRI) [Study Day 0 to Study Day 84]

Eligibility Criteria

Criteria

Ages Eligible for Study:
25 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Subjects 25-80 years of age.

  • Ability to understand and speak English, follow written and verbal instructions (English), and give informed consent (English), as assessed by study staff.

  • Ability to comply with all the testing and study requirements, including the ability to independently use a video conferencing tool and the ability to independently use a computer to access the web.

  • Ability to independently complete a daily, online intervention and outcome assessments using a web browser compatible with the intervention and assessment software on a reliable, internet-connected laptop or desktop computer.

Exclusion Criteria:
  • Current, controlled (requiring treatment) or uncontrolled psychiatric diagnosis, including but not limited to posttraumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder, conduct disorder, attention-deficit/hyperactivity disorder, or other symptomatic manifestations that in the opinion of the Investigator may confound study data/assessments.

  • Current, controlled (requiring treatment) or uncontrolled neurological diagnosis, including but not limited to Alzheimer's Disease, other dementias, mild cognitive impairment, Huntington's Disease, Parkinson's Disease, multiple sclerosis, stroke, epilepsy, aphasia, or other condition that in the opinion of the Investigator may confound study data/assessments.

  • Any other medical condition in the last 90 days that in the opinion of the Investigator may confound study data/assessments.

  • Has been under the care of a caretaker or has not been living independently in the last 90 days.

  • In the last three years has used any of the following for more than two weeks continuously: Online courses, Online brain training programs

  • Known sensitivity (such as headaches, dizziness, nausea) to bright, stimulating video displays.

  • History of seizures (excluding febrile seizures), or significant motor or vocal tics, including but not limited to Tourette's Disorder and photo-sensitive epilepsy.

  • Visual acuity that cannot be corrected that prevents or negatively impacts computer activity.

  • Has participated in a clinical trial within 90 days prior to screening.

  • Pregnancy or planning to become pregnant.

Additional Exclusion Criteria for Cohort B only:
  • Unwillingness or inability to comply with imaging safety protocols.

  • Metal implants or exposure to shrapnel.

  • Left-handed or ambidextrous.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Lumos Labs, Inc. San Francisco California United States 94108

Sponsors and Collaborators

  • Lumos Labs, Inc.

Investigators

  • Principal Investigator: Kevin Madore, PhD, Lumos Labs, Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Lumos Labs, Inc.
ClinicalTrials.gov Identifier:
NCT05912556
Other Study ID Numbers:
  • LL-015
First Posted:
Jun 22, 2023
Last Update Posted:
Jun 22, 2023
Last Verified:
Jun 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Jun 22, 2023